Pegylated IL‐10 induces cancer immunity: The surprising role of IL‐10 as a potent inducer of IFN‐γ‐mediated CD8+ T cell cytotoxicity
The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Abstract
Recently, the development of several strategies based on immunotherapy has raised hopes for a more promising way to treat cancer patients. Here, we describe how interleukin (IL)‐10, a seemingly unlikely candidate, stimulates the immune system in a particularly efficacious way. IL‐10, an omnipotent anti‐inflammatory cytokine, delivers an equally potent immune stimulation in the context of CD8+ T cells and tumor immunity. By activation of tumor‐resident, tumor‐specific CD8+ T cells, pegylated IL‐10 can induce rejection of large and metastasizing tumors in mice. Here, we summarize the mechanisms of action of IL‐10, the reasons why the mechanisms may be crucial for the treatment of cancer patients, and the rationale for applying pegylated IL‐10 in the clinic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Interleukin-10 and the Interleukin-10 Receptor
Moore, K. W., de Waal Malefyt, R., Coffman, R. L., & O'Garra, A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.683 · Cited by 6,737
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
IL-10 inhibits cytokine production by activated macrophages
Fiorentino, D. F., Zlotnik, A., Mosmann, T. R., Howard, M., & O’Garra, A. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.11.3815 · Cited by 2,888
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
de Waal Malefyt, R., Haanen, J., Spits, H., Roncarolo, M. G., te Velde, A., Figdor, C., Johnson, K., Kastelein, R., Yssel, H., & de Vries, J. E. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.4.915 · Cited by 1,930
Antigen Presentation and T Cell Stimulation by Dendritic Cells
Guermonprez, P., Valladeau, J., Zitvogel, L., Théry, C., & Amigorena, S. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064828 · Cited by 1,926
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
The JAK-STAT Signaling Pathway: Input and Output Integration
Murray, P. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.2623 · Cited by 1,179
Distinct Effects of T-bet in T H 1 Lineage Commitment and IFN-γ Production in CD4 and CD8 T Cells
Szabo, S. J., Sullivan, B. M., Stemmann, C., Satoskar, A. R., Sleckman, B. P., & Glimcher, L. H. (2002) · Science · doi:10.1126/science.1065543 · Cited by 1,172
Berg, D. J., Davidson, N., Kühn, R., Müller, W., Menon, S., Holland, G., Thompson-Snipes, L., Leach, M. W., & Rennick, D. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118861 · Cited by 1,136
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
Lee, P. P., Yee, C., Savage, P. A., Fong, L., Brockstedt, D., Weber, J. S., Johnson, D., Swetter, S., Thompson, J., Greenberg, P. D., et al. (1999) · Nature Medicine · doi:10.1038/9525 · Cited by 1,113
Chaudhry, A., Samstein, R. M., Treuting, P., Liang, Y., Pils, M. C., Heinrich, J.-M., Jack, R. S., Wunderlich, F. T., Brüning, J. C., Müller, W., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.03.018 · Cited by 980
TNF-α in promotion and progression of cancer
Balkwill, F. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9005-3 · Cited by 915
Leonard, J. P., Sherman, M. L., Fisher, G. L., Buchanan, L. J., Larsen, G., Atkins, M. B., Sosman, J. A., Dutcher, J. P., Vogelzang, N. J., & Ryan, J. L. (1997) · PubMed · Cited by 820
Th17 Cell Differentiation: The Long and Winding Road
McGeachy, M. J., & Cua, D. J. (2008) · Immunity · doi:10.1016/j.immuni.2008.03.001 · Cited by 701
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma
Daud, A. I., DeConti, R. C., Andrews, S., Urbas, P., Riker, A. I., Sondak, V. K., Munster, P. N., Sullivan, D. M., Ugen, K. E., Messina, J. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6794 · Cited by 701
Atkins, M. B., Robertson, M. J., Gordon, M. S., Lotze, M. T., DeCoste, M., DuBois, J. S., Ritz, J., Sandler, A. B., Edington, H. D. J., Garzone, P. D., et al. (1997) · PubMed · Cited by 672
Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells
Chen, Z., Laurence, A., Kanno, Y., Pacher-Zavisin, M., Zhu, B.-M., Tato, C., Yoshimura, A., Hennighausen, L., & O'Shea, J. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600666103 · Cited by 653
Rosenberg, S. A., Lotze, M. T., Yang, J. C., Topalian, S. L., Chang, A. E., Schwartzentruber, D. J., Aebersold, P., Leitman, S., Linehan, W. M., Seipp, C. A., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.8.622 · Cited by 639
SOCS regulation of the JAK/STAT signalling pathway
Croker, B. A., Kiu, H., & Nicholson, S. E. (2008) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2008.07.010 · Cited by 611
Rosenberg, S. A., Sherry, R. M., Morton, K. E., Scharfman, W. J., Yang, J. C., Topalian, S. L., Royal, R. E., Kammula, U., Restifo, N. P., Hughes, M. S., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.6169 · Cited by 465
Finbloom, D. S., & Winestock, K. D. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1079 · Cited by 421
IL-10 Elicits IFNγ-Dependent Tumor Immune Surveillance
Mumm, J. B., Emmerich, J., Zhang, X., Chan, I., Wu, L., Mauze, S., Blaisdell, S., Basham, B., Dai, J., Grein, J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.003 · Cited by 418
Self-citationEpitope Landscape in Breast and Colorectal Cancer
Segal, N. H., Parsons, D. W., Peggs, K. S., Velculescu, V., Kinzler, K. W., Vogelstein, B., & Allison, J. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3095 · Cited by 416
Donnelly, R. P., Dickensheets, H., & Finbloom, D. S. (1999) · Journal of Interferon & Cytokine Research · doi:10.1089/107999099313695 · Cited by 413
Cui, W., Liu, Y., Weinstein, J. S., Craft, J., & Kaech, S. M. (2011) · Immunity · doi:10.1016/j.immuni.2011.09.017 · Cited by 410
Dendritic cells: Understanding immunogenicity
Steinman, R. M. (2007) · European Journal of Immunology · doi:10.1002/eji.200737400 · Cited by 401
Williams, L., Bradley, L., Smith, A., & Foxwell, B. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.567 · Cited by 393
IL-10: a novel cytotoxic T cell differentiation factor
Chen, W. F., & Zlotnik, A. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.2.528 · Cited by 382
Kotenko, S. V., Krause, C. D., Izotova, L. S., Pollack, B. P., Wu, W., & Pestka, S. (1997) · The EMBO Journal · doi:10.1093/emboj/16.19.5894 · Cited by 381
Vicari, A. P., Chiodoni, C., Vaure, C., Aït-Yahia, S., Dercamp, C., Matsos, F., Reynard, O., Taverne, C., Merle, P., Colombo, M. P., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020732 · Cited by 343
Expression cloning and characterization of a human IL-10 receptor.
Liu, Y., Wei, S. H., Ho, A. S. Y., de Waal Malefyt, R., & Moore, K. W. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.4.1821 · Cited by 321
Proinflammatory Effects of IL-10 During Human Endotoxemia
Lauw, F. N., Pajkrt, D., Hack, C. E., Kurimoto, M., van Deventer, S. J. H., & van der Poll, T. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.5.2783 · Cited by 318
Zhang, J.-Y., Zhang, Z., Wang, X., Fu, J.-L., Yao, J., Jiao, Y., Chen, L., Zhang, H., Wei, J., Jin, L., et al. (2007) · Blood · doi:10.1182/blood-2006-09-044826 · Cited by 302
Therapeutic Cancer Vaccines: Current Status and Moving Forward
Schlom, J. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs033 · Cited by 282
Siegel, A. M., Heimall, J., Freeman, A. F., Hsu, A. P., Brittain, E., Brenchley, J. M., Douek, D. C., Fahle, G. H., Cohen, J. I., Holland, S. M., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.09.016 · Cited by 278
Wang, W., Lau, R., Yu, D., Zhu, W., Korman, A., & Weber, J. (2009) · International Immunology · doi:10.1093/intimm/dxp072 · Cited by 277
Tilg, H., van Montfrans, C., van den Ende, A., Kaser, A., van Deventer, S. J. H., Schreiber, S., Gregor, M., Ludwiczek, O., Rutgeerts, P., Gasche, C., et al. (2002) · Gut · doi:10.1136/gut.50.2.191 · Cited by 272
Emmerich, J., Mumm, J. B., Chan, I. H., LaFace, D., Truong, H., McClanahan, T., Gorman, D. M., & Oft, M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0721 · Cited by 270
Self-citationGroux, H., Cottrez, F., Rouleau, M., Mauze, S., Antonenko, S., Hurst, S., McNeil, T., Bigler, M., Roncarolo, M.-G., & Coffman, R. L. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.3.1723 · Cited by 247
Interleukin‐10 suppression of myeloid cell activation — a continuing puzzle
Williams, L. M., Ricchetti, G., Sarma, U., Smallie, T., & Foxwell, B. M. J. (2004) · Immunology · doi:10.1111/j.1365-2567.2004.01988.x · Cited by 234
Wong, R. M., Scotland, R. R., Lau, R. L., Wang, C., Korman, A. J., Kast, W. M., & Weber, J. S. (2007) · International Immunology · doi:10.1093/intimm/dxm091 · Cited by 231
Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism.
Zheng, L. M., Ojcius, D. M., Garaud, F., Roth, C., Maxwell, E., Li, Z., Rong, H., Chen, J., Wang, X. Y., Catino, J. J., et al. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.2.579 · Cited by 230
TGF‐β: a mobile purveyor of immune privilege
Wahl, S. M., Wen, J., & Moutsopoulos, N. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00437.x · Cited by 229
How Diverse--CD4 Effector T Cells and their Functions
Wan, Y. Y., & Flavell, R. A. (2009) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjp001 · Cited by 222
Ha, S.-J., Mueller, S. N., Wherry, E. J., Barber, D. L., Aubert, R. D., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071949 · Cited by 211
CD4+CD25+ Regulatory Lymphocytes Induce Regression of Intestinal Tumors in ApcMin/+ Mice
Erdman, S. E., Sohn, J. J., Rao, V. P., Nambiar, P. R., Ge, Z., Fox, J. G., & Schauer, D. B. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3104 · Cited by 211
Interleukin-10 promotes the maintenance of antitumor CD8+ T-cell effector function in situ
Fujii, S.-I., Shimizu, K., Shimizu, T., & Lotze, M. T. (2001) · Blood · doi:10.1182/blood.v98.7.2143 · Cited by 208
Berman, R. M., Suzuki, T., Tahara, H., Robbins, P. D., Narula, S. K., & Lotze, M. T. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.1.231 · Cited by 205
Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells.
Seliger, B., Wollscheid, U., Momburg, F., Blankenstein, T. J. F., & Huber, C. (2001) · PubMed · Cited by 195
IL-10 enhances NK cell proliferation, cytotoxicity and production of IFN-γ when combined with IL-18
Cai, G., Kastelein, R. A., & Hunter, C. A. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199909)29:09<2658::aid-immu2658>3.0.co;2-g · Cited by 191
El Kasmi, K. C., Smith, A. M., Williams, L., Neale, G., Panopolous, A., Watowich, S. S., Häcker, H., Foxwell, B. M. J., & Murray, P. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.11.7215 · Cited by 182
Giovarelli, M., Musiani, P., Modesti, A., Dellabona, P., Casorati, G., Allione, A., Consalvo, M., Cavallo, F., di Pierro, F., & De Giovanni, C. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.6.3112 · Cited by 180
Norde, W. J., Maas, F., Hobo, W., Korman, A., Quigley, M., Kester, M. G. D., Hebeda, K., Falkenburg, J. H. F., Schaap, N., de Witte, T. M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0108 · Cited by 167
The Lethal Phenotype of Cancer: The Molecular Basis of Death Due to Malignancy
Loberg, R. D., Bradley, D. A., Tomlins, S. A., Chinnaiyan, A. M., & Pienta, K. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.4.225 · Cited by 161
Antimetastatic and Antitumor Activities of Interleukin 10 in a Murine Model of Breast Cancer
Kundu, N., Beaty, T. L., Jackson, M. J., & Fulton, A. M. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.8.536 · Cited by 154
Interleukin 10 Treatment of Psoriasis: Clinical Results of a Phase 2 Trial
Asadullah, K., Döcke, W.-D., Ebeling, M., Friedrich, M., Belbe, G., Audring, H., Volk, H.-D., & Sterry, W. (1999) · Archives of Dermatology · doi:10.1001/archderm.135.2.187 · Cited by 151
Cytokine-Based Therapy and Biochemotherapy for Advanced Melanoma
Atkins, M. B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2503 · Cited by 149
Reprogramming of IL-10 Activity and Signaling by IFN-γ
Herrero, C., Hu, X., Li, W. P., Samuels, S., Sharif, M. N., Kotenko, S., & Ivashkiv, L. B. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.10.5034 · Cited by 147
Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study
Petrella, T. M., Tozer, R., Belanger, K., Savage, K. J., Wong, R., Smylie, M., Kamel-Reid, S., Tron, V., Chen, B. E., Hunder, N. N., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.0655 · Cited by 126
Negative regulation of MyD88-dependent signaling by IL-10 in dendritic cells
Chang, J., Kunkel, S. L., & Chang, C.-H. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905815106 · Cited by 125
NFIL3 Is a Regulator of IL-12 p40 in Macrophages and Mucosal Immunity
Kobayashi, T., Matsuoka, K., Sheikh, S. Z., Elloumi, H. Z., Kamada, N., Hisamatsu, T., Hansen, J. J., Doty, K. R., Pope, S. D., Smale, S. T., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003888 · Cited by 118
Crawley, J. B., Williams, L. M., Mander, T., Brennan, F. M., & Foxwell, B. M. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.27.16357 · Cited by 99
Takeda, K., Kojima, Y., Uno, T., Hayakawa, Y., Teng, M. W. L., Yoshizawa, H., Yagita, H., Gejyo, F., Okumura, K., & Smyth, M. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903033 · Cited by 82
Zhou, J.-H., Broussard, S. R., Strle, K., Freund, G. G., Johnson, R. W., Dantzer, R., & Kelley, K. W. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.8.4436 · Cited by 79
Adris, S., Klein, S., Jasnis, M. A., Chuluyán, E., Ledda, M. F., Bravo, A., Carbone, C., Chernajovsky, Y., & Podhajcer, O. L. (1999) · Gene Therapy · doi:10.1038/sj.gt.3301012 · Cited by 72
Stat3-Dependent Induction of p19INK4D by IL-10 Contributes to Inhibition of Macrophage Proliferation
O’Farrell, A.-M., Parry, D. A., Zindy, F., Roussel, M. F., Lees, E., Moore, K. W., & Mui, A. L. F. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.9.4607 · Cited by 64
IL-15-Induced IL-10 Increases the Cytolytic Activity of Human Natural Killer Cells
Park, J. Y., Lee, S. H., Yoon, S. R., Park, Y., Jung, H., Kim, T., & Choi, I. (2011) · Molecules and Cells · doi:10.1007/s10059-011-1057-8 · Cited by 64
Peptide database of T-cell defined tumor antigens
van der Bruggen, P., Stroobant, V., Vigneron, N., & den Eynde, B. J. V. (2013) · Digital Access to Libraries · Cited by 46
Soria, J., Moon, C., Kemp, B. L., Liu, D. D., Feng, L., Tang, X., Chang, Y. S., Mao, L., & Khuri, F. R. (2003) · PubMed · Cited by 45
Walsh, M. D., Dent, O. F., Young, J. P., Wright, C. M., Barker, M. A., Leggett, B. A., Bokey, L., Chapuis, P. H., Jass, J. R., & Macdonald, G. A. (2009) · International Journal of Cancer · doi:10.1002/ijc.24484 · Cited by 41
Interleukin 21 Enhances Antibody-Mediated Tumor Rejection
Smyth, M. J., Teng, M. W. L., Sharkey, J., Westwood, J. A., Haynes, N. M., Yagita∥, H., Takeda, K., Sivakumar, P. V., & Kershaw, M. H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6019 · Cited by 28
Human Papillomavirus-Specific Immune Therapy: Failure and Hope
Nieto, K., Gissmann, L., & Schädlich, L. (2010) · Antiviral Therapy · doi:10.3851/imp1665 · Cited by 25
IL-23 orchestrates the switch from tumor immune surveillance to tumor-promoting inflammation
Oft, M. (2009) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8681-8_14 · Cited by 2
Self-citation
Cited by
Current status of interleukin-10 and regulatory T-cells in cancer
Dennis, K. L., Blatner, N. R., Gounari, F., & Khazaie, K. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000006 · Cited by 289
“Unau Health | Lippincott Williams & Wilk expectation, protective roles for IL-10 in cancer are emerging that stimulate a fresh look at the functions of this cytokine and of its cellular sources [17].”
BackgroundCytokines in CAR T Cell–Associated Neurotoxicity
Gust, J., Ponce, R., Liles, W. C., Garden, G. A., & Turtle, C. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.577027 · Cited by 264
T lymphocyte subsets in cancer immunity: Friends or foes
Chraa, D., Naim, A., Olive, D., & Badou, A. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr0318-097r · Cited by 172
Serum IL-10 Predicts Worse Outcome in Cancer Patients: A Meta-Analysis
Zhao, S., Wu, D., Wu, P., Wang, Z., & Huang, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139598 · Cited by 164
IL-10-producing T cells and their dual functions
Bedke, T., Muscate, F., Soukou, S., Gagliani, N., & Huber, S. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101335 · Cited by 152
Metadata
- Authors
- Mumm, J. B., & Oft, M.
- Affiliations
- ARMO Biosciences Redwood City CA USA
- Corresponding author
- Oft, Martin
- Venue
- BioEssays
- Publisher
- Wiley
- Published
- 2013-05-13
- Volume
- 35
- Issue
- 7
- Pages
- 623-631
- ISSN
- 0265-9247 (ISSN-L)
- 1521-1878
- OpenAlex
- W2166586868
- Cited by
- 53
- References
- 81
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 4 · 2020: 9 · 2019: 4 · 2018: 5 · 2017: 5 · 2016: 1 · 2015: 8 · 2014: 2 · 2013: 1
- FWCI
- 0.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- BioEssays (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- IL-10, cancer immunotherapy, CD8+ T cells, antitumor immunity, tumor rejection, metastasis, anti-inflammatory cytokines, immunostimulation
- MeSH terms
- Animals, Disease Models, Animal, Humans, Immunotherapy, Interferon-gamma, Neoplasms, Polyethylene Glycols, Interleukin-10, CD8-Positive T-Lymphocytes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.